Emerging therapies for multiple myeloma

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

(2008) A. Palumbo et al.   BLOOD

CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3  and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions

(2008) N. Giuliani et al.   CANCER RESEARCH

Guggulsterone, a Farnesoid X Receptor Antagonist, Inhibits Constitutive and Inducible STAT3 Activation through Induction of a Protein Tyrosine Phosphatase SHP-1

(2008) K. S. Ahn et al.   CANCER RESEARCH

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH

Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment

(2008) A. Huston et al.   CLINICAL CANCER RESEARCH

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

(2008) H. M. Lokhorst et al.   HAEMATOLOGICA

Osteoclast Precursor Interaction with Bone Matrix Induces Osteoclast Formation Directly by an Interleukin-1-mediated Autocrine Mechanism

(2008) Zhenqiang Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

(2008) H Paripati et al.   LEUKEMIA

Genetic aberrations and survival in plasma cell leukemia

(2008) R E Tiedemann et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE